|
Video: What is a Stock Split?
|
|
Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focused on advancing eganelisib (IPI-549), an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat various solid tumors and represents an additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. Further, preclinical studies showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy. According to our INFI split history records, INFI has had 1 split. | |
|
INFI (INFI) has 1 split in our INFI split history database. The split for INFI took place on September 13, 2006. This was a 1 for 4 reverse split, meaning for each 4 shares of INFI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
When a company such as INFI conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the INFI split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into INFI shares, starting with a $10,000 purchase of INFI, presented on a split-history-adjusted basis factoring in the complete INFI split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
09/29/2023 |
|
Start price/share: |
$11.89 |
|
End price/share: |
$0.02 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.83% |
|
Average Annual Total Return: |
-48.94% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$16.81 |
|
Years: |
9.50 |
|
|
|
Date |
Ratio |
09/13/2006 | 1 for 4 |
|
|